<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00066274</url>
  </required_header>
  <id_info>
    <org_study_id>Accord 08</org_study_id>
    <secondary_id>FRE-FNCLCC-ACCORD-08/0103</secondary_id>
    <secondary_id>EU-20233</secondary_id>
    <nct_id>NCT00066274</nct_id>
  </id_info>
  <brief_title>Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>Randomized Phase II Study Evaluating Three Chemotherapies: [Irinotecan + Oxaliplatin (Irinox)], [Irinotecan + LV5FU2] and [Oxaliplatin + LV5FU2] as First Intention Treatment in Subjects With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Giving the drugs in different combinations may kill more tumor&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying combination chemotherapy containing&#xD;
      irinotecan and oxaliplatin to see how well it works compared to two standard combination&#xD;
      chemotherapy regimens in treating patients with unresectable metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy, in terms of response rate (partial response and complete&#xD;
           response), of irinotecan and oxaliplatin vs irinotecan, fluorouracil, and leucovorin&#xD;
           calcium vs oxaliplatin, fluorouracil, and leucovorin calcium in patients with metastatic&#xD;
           colorectal cancer.&#xD;
&#xD;
        -  Compare the progression-free survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the tolerability of these regimens in these patients.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 3 treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients receive irinotecan IV over 90 minutes and oxaliplatin IV over 2 hours on&#xD;
           day 1.&#xD;
&#xD;
        -  Arm II: Patients receive irinotecan IV over 90 minutes and leucovorin calcium IV over 2&#xD;
           hours on day 1 and fluorouracil IV over 46 hours on days 1-2.&#xD;
&#xD;
        -  Arm III: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2&#xD;
           hours on day 1 and fluorouracil IV over 46 hours on days 1-2.&#xD;
&#xD;
      In all arms, treatment repeats every 2 weeks for 26 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline and then every 3 months for 1 year.&#xD;
&#xD;
      Patients are followed at 2 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 23, 2002</start_date>
  <completion_date type="Actual">April 1, 2007</completion_date>
  <primary_completion_date type="Actual">November 4, 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed colorectal carcinoma&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  Not amenable to surgery&#xD;
&#xD;
          -  Unidimensionally measurable disease&#xD;
&#xD;
          -  No bone metastases&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 75&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Neutrophil count at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.25 times upper limit of normal (ULN) (1.5 times ULN if&#xD;
             hepatic metastases are present)&#xD;
&#xD;
          -  SGPT and SGOT no greater than 3 times ULN (5 times ULN if hepatic metastases are&#xD;
             present)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.25 times ULN&#xD;
&#xD;
        Cardiac&#xD;
&#xD;
          -  No concurrent cardiac abnormalities that would preclude study therapy&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No concurrent pulmonary abnormalities that would preclude study therapy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No chronic enteropathy&#xD;
&#xD;
          -  No other prior cancer within the past 5 years except carcinoma in situ of the cervix&#xD;
             or curatively treated basal cell skin cancer&#xD;
&#xD;
          -  No concurrent severe uncontrolled infection&#xD;
&#xD;
          -  No obstruction or partial obstruction that would interfere with study therapy&#xD;
&#xD;
          -  No psychological, social, familial, or geographical situation that would preclude&#xD;
             study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent anticancer biological response modifiers&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy (except adjuvant chemotherapy completed more than 6 months ago)&#xD;
&#xD;
          -  No prior irinotecan&#xD;
&#xD;
          -  No prior oxaliplatin&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent anticancer hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior pelvic radiotherapy&#xD;
&#xD;
          -  No prior abdominopelvic radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 4 weeks since prior surgery&#xD;
&#xD;
          -  No prior extensive intestinal resection (i.e., more than 1 prior hemicolectomy or&#xD;
             extensive resection of the small intestines)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent experimental medication&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Becouarn, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier de L' Agglomeration Montargoise</name>
      <address>
        <city>Amilly</city>
        <zip>45207</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pole Sante Sarthe et Loir Hopital Pierre Daguet</name>
      <address>
        <city>Angers</city>
        <zip>49036</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte-Marguerite</name>
      <address>
        <city>Hyeres</city>
        <zip>83400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Departemental</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>F-85025</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR D'Orleans - Hopital de la Source</name>
      <address>
        <city>Orleans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Francheville</name>
      <address>
        <city>Perigueux</city>
        <zip>24004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35062</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHG Roanne</name>
      <address>
        <city>Roanne</city>
        <zip>F-42300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Rodez</name>
      <address>
        <city>Rodez</city>
        <zip>12027</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional Metz Thionville</name>
      <address>
        <city>Thionville</city>
        <zip>57126</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier General Lucien Hussel</name>
      <address>
        <city>Vienne</city>
        <zip>38200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Bécouarn Y, Senesse P, Thézenas S, Boucher E, Adenis A, Cany L, Jacob JH, Cvitkovic F, Montoto-Grillot C, Ychou M; Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer. A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer. Ann Oncol. 2007 Dec;18(12):2000-5. Epub 2007 Sep 4.</citation>
    <PMID>17785765</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 6, 2003</study_first_submitted>
  <study_first_submitted_qc>August 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2003</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

